Hematopathology Practice Questions

Q: A patient with anemia has a reticulocyte count of 6% and a hematocrit of 30%. What is the clinical significance of the corrected reticulocyte count?

4%, indicating an appropriate response to anemia.. 4%, indicating an appropriate bone marrow response - A corrected reticulocyte count of 4% shows that the bone marrow is responding adequately to the anemia, especially in the presence of an increased reticulocyte percentage relative to hematocrit. - This suggests that there is effective erythropoiesis, often seen in conditions like hemolytic anemia or recovery from blood loss. 6%, suggesting ineffective erythropoiesis - A reticulocyte count of 6% alone does not indicate ineffective erythropoiesis; rather, it points towards a reactive process by the bone marrow. - If ineffective, we would typically expect a lower reticulocyte count due to poor response despite anemia. 2%, indicating an inadequate bone marrow response - A 2% reticulocyte count suggests that the bone marrow is not responding effectively to the anemia, which contradicts the given high count of 6%. - This would be more indicative of conditions like aplasia or renal failure rather than the scenario presented. 3%, consistent with iron deficiency anemia - A count of 3% does not appropriately represent the reticulocyte response in iron deficiency anemia, which usually would show a lower reticulocyte count in severe cases. [1] - Iron deficiency typically leads to microcytic anemia with low reticulocyte production due to inadequate iron for hemoglobin synthesis. [1]

Q: Which immunohistochemical markers assist in the diagnosis of follicular lymphoma?

CD10 and BCL2. ***CD10 and BCL2*** - These markers are crucial in follicular lymphoma, with **CD10** indicating germinal center origin [2][3] and **BCL2** demonstrating the anti-apoptotic effect that contributes to neoplastic proliferation [1][2][3]. - The presence of both these markers is commonly used to characterize **follicular lymphoma**, distinguishing it from other lymphomas [1]. *CD30 and CD15* - These markers are typically associated with **Reed-Sternberg cells** in **Hodgkin lymphoma**, not follicular lymphoma. - Their presence indicates different **malignant lymphoproliferative disorders** unrelated to follicular lymphoma. *CD20 and CD23* - While CD20 is a pan B-cell marker found in many B-cell neoplasms, CD23 is more indicative of **chronic lymphocytic leukemia (CLL)** and not specific to follicular lymphoma. - They do not combine the critical features needed to diagnose follicular lymphoma effectively. *CD3 and CD7* - These are T-cell markers and do not apply to follicular lymphoma, which is a B-cell neoplasm [2][3]. - Their presence indicates T-cell malignancies rather than the **germinal center B-cell** derivation typical of follicular lymphoma [2][3]. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Diseases of White Blood Cells, Lymph Nodes, Spleen, and Thymus, p. 604. [2] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Diseases of White Blood Cells, Lymph Nodes, Spleen, and Thymus, pp. 602-604. [3] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. Common Clinical Problems From Diseases Of The Urinary And Male Genital Tracts, pp. 561-562.

Q: In a patient with hemolytic anemia, which of the following laboratory findings is most likely to be elevated?

Reticulocyte count. ***Reticulocyte count*** - In **hemolytic anemia**, there's increased destruction of red blood cells, prompting the bone marrow to produce more, leading to an **elevated reticulocyte count** as it tries to compensate. - A high reticulocyte count indicates that the **bone marrow is actively responding** to the anemia. *Haptoglobin* - **Haptoglobin** binds to free hemoglobin released during red blood cell destruction. - In **hemolytic anemia**, haptoglobin levels are typically **decreased** or undetectable rather than elevated, as it is consumed in binding the excess free hemoglobin. *Indirect Bilirubin* - **Indirect bilirubin** is indeed typically elevated in hemolytic anemia due to the increased breakdown of hemoglobin and subsequent heme metabolism [1]. - However, the question asks for the *most likely* to be elevated; an **elevated reticulocyte count** is a more direct and specific indicator of increased red cell turnover due to hemolysis. *Serum Ferritin* - **Serum ferritin** reflects the body's iron stores. While chronic hemolysis can eventually lead to **iron overload** (and thus elevated ferritin) in some cases, it is not an immediate or universal finding for diagnosing acute hemolysis. - In many cases of hemolytic anemia, especially acute presentations, **ferritin levels may be normal** or even slightly low if there's concurrent iron deficiency.

Q: A 5-year-old child presents with fatigue, petechiae, and hepatosplenomegaly. Laboratory results show low hemoglobin, low platelets, and high white blood cell count. The peripheral smear reveals blasts with Auer rods. What is the diagnosis?

Acute myeloid leukemia. ***Acute myeloid leukemia*** - The presence of **blasts with Auer rods** is characteristic of acute myeloid leukemia [1], which fits the laboratory findings of **low hemoglobin** and **low platelets**. - Symptoms like **fatigue**, **petechiae**, and **hepatosplenomegaly** further support this diagnosis, indicating bone marrow infiltration [1]. *Chronic myeloid leukemia* - Typically presents in older adults and is characterized by the presence of **Philadelphia chromosome** and elevated **white blood cell count** with a predominance of mature cells rather than blasts. - Fatigue and splenomegaly may occur but are not common in a child this young at the acute presentation. *Acute lymphoblastic leukemia* - Generally affects young children [2] but is characterized by **lymphoblasts** on the peripheral smear, rather than **myeloid blasts with Auer rods**. - Usually presents with a **high white blood cell count**, but symptoms differ as lymphoid infiltration is predominant. *Chronic lymphocytic leukemia* - Rarely seen in children; it typically involves an **overproduction of mature lymphocytes** and chronic lymphadenopathy rather than acute symptoms like **petechiae** or **fatigue**. - Associated with **elevated white blood cell count** with a predominance of mature lymphocytes and chronic presentations, contrasting with the acute nature of this case. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Diseases of White Blood Cells, Lymph Nodes, Spleen, and Thymus, pp. 621-622. [2] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. Common Clinical Problems From Blood And Bone Marrow Disease, pp. 607-608.

Q: Which formula is essential for calculating the corrected reticulocyte count in an anemic patient?

(Reticulocyte count × Hematocrit) / 45. **(Reticulocyte count × Hematocrit) / 45** - This formula is used to calculate the **corrected reticulocyte count (CRC)**, which adjusts the observed reticulocyte percentage for the degree of **anemia**. - The value **'45' represents the normal hematocrit percentage** used as the standard for comparison [1]. * (Reticulocyte count × Hematocrit) / 50* - This formula uses an **incorrect normal hematocrit value** of 50%, which is typically higher than the average normal hematocrit for most adults. - Using an inaccurate reference hematocrit value would lead to an **overestimation of the corrected reticulocyte count**. * (Reticulocyte count × Hematocrit) / 40* - This formula uses an **incorrect normal hematocrit value** of 40%, which is generally on the lower end of the normal range or slightly below for adult males. - This could potentially **overestimate the bone marrow's reticulocyte production** in anemic individuals, depending on the patient's actual normal hematocrit level. * (Reticulocyte count × Hematocrit) / 30* - This formula uses a value of **30% as the normal hematocrit**, which is significantly lower than the accepted normal range. - Using such a low reference value would lead to a **substantial overestimation of the corrected reticulocyte count**, potentially misleading the assessment of erythropoietic activity. **References:** [1] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. Common Clinical Problems From Blood And Bone Marrow Disease, pp. 577-578.

Q: Which disease is characterized by the absence of the CD59 protein?

Paroxysmal Nocturnal Hemoglobinuria (PNH). ***PNH*** - CD59 is a **glycoprotein** that inhibits the formation of the membrane attack complex of the complement system, which is deficient in **Paroxysmal Nocturnal Hemoglobinuria (PNH)** [1][2]. - The presence of CD59 deficiency leads to **hemolysis** and manifestations like **dark urine**, especially in the morning [1]. *BRR* - Refers to **Bloom-Richardson Grade** in breast cancer pathology, not related to CD59. - It focuses more on **histological features** rather than specific **markers** like CD59. *PTEN* - PTEN is a **tumor suppressor gene** associated with various cancers, particularly in **Cowden syndrome** and **PTEN hamartoma syndrome**. - It does not relate to the **CD59 deficiency** found in PNH. *Cowden syndrome* - Cowden syndrome is linked to mutations in the **PTEN gene**, leading to numerous hamartomas and an increased risk for breast and thyroid cancers. - It does not exhibit any relationship with **CD59**, which is specifically associated with PNH. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Red Blood Cell and Bleeding Disorders, pp. 650-651. [2] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. Common Clinical Problems From Blood And Bone Marrow Disease, pp. 601-602.

Q: Which gene is commonly overexpressed in follicular lymphoma?

Bcl-2. ***Bcl- 2*** - Follicular lymphoma is characteristically associated with the **overexpression of Bcl-2** [1][2], which prevents apoptosis and contributes to oncogenesis [1][3]. - It is a result of the **t(14;18)** translocation, leading to the fusion of the Bcl-2 gene with the immunoglobulin heavy chain locus [1][2][3]. *Bcl-6* - While Bcl-6 is involved in the pathogenesis of some lymphomas, including **diffuse large B-cell lymphoma** [4], it is not a defining feature of follicular lymphoma. - Its positivity in follicular lymphoma cases does not correlate with the diagnosis. *None of the above* - This option is incorrect as there is a clear association with **Bcl-2** [1][2], which is pivotal in the pathology of follicular lymphoma. - Saying "none of the above" overlooks the critical marker essential for diagnosis. *Bcl-1* - Bcl-1 is primarily linked to **mantle cell lymphoma**, not follicular lymphoma, making it an unsuitable choice. - It is associated with **t(11;14)** translocations and has a different role in lymphoid malignancies compared to Bcl-2. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Diseases of White Blood Cells, Lymph Nodes, Spleen, and Thymus, pp. 602-604. [2] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. Common Clinical Problems From Diseases Of The Urinary And Male Genital Tracts, pp. 561-562. [3] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Neoplasia, pp. 310-311. [4] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Diseases of White Blood Cells, Lymph Nodes, Spleen, and Thymus, p. 604.

Q: Which of the following statements about sideroblastic anemia is correct?

Prussian blue staining reveals ringed sideroblasts. ***Prussian blue staining reveals ringed sideroblasts*** - Sideroblastic anemia is characterized by the presence of **ringed sideroblasts** in the bone marrow, which are erythroblasts with iron granules accumulating in a ring around the nucleus. - These iron deposits are visible with **Prussian blue staining**, confirming the diagnosis. *Severity of the disease is influenced by ALA synthase activity* - While defects in **heme synthesis** can cause sideroblastic anemia, the severity is not primarily or solely determined by **ALA synthase activity**. - Sideroblastic anemias involve diverse genetic and acquired causes, affecting various enzyme steps and pathways, not just specifically ALA synthase. *All of the options are false* - This statement is incorrect because the presence of **ringed sideroblasts** seen with Prussian blue staining is a hallmark diagnostic feature of sideroblastic anemia, making that option true. - This option would only be true if all other statements were false, which is not the case here. *Pyridoxine supplementation is the definitive treatment for all types of sideroblastic anemia* - **Pyridoxine (vitamin B6)** is a cofactor for some enzymes in the heme synthesis pathway, and about one-third of congenital sideroblastic anemias respond to it. - However, it is not a definitive treatment for **all types of sideroblastic anemia**, especially acquired forms or those with specific genetic mutations not responsive to pyridoxine.

Q: Which of the following genes is most commonly mutated in Juvenile myelomonocytic leukemia (JMML)?

PTPN11. ***PTPN11*** - **PTPN11** encodes the SHP2 protein, a non-receptor protein tyrosine phosphatase that plays a crucial role in the **RAS-MAPK signaling pathway**. - **Germline or somatic mutations** in PTPN11 are found in approximately **35% of JMML cases**, making it the **most commonly mutated gene** in this disorder. - These gain-of-function mutations lead to constitutive activation of RAS signaling, driving the myeloproliferative phenotype characteristic of JMML. - PTPN11 mutations are also associated with **Noonan syndrome**, and patients with Noonan syndrome have an increased risk of developing JMML. *KRAS* - **KRAS** is a proto-oncogene encoding a GTPase in the RAS-MAPK pathway. Mutations cause constitutive activation and uncontrolled cell proliferation. - KRAS mutations are found in approximately **15-20% of JMML cases**, making it the **second most common** genetic alteration in this disease. - While definitely associated with JMML, KRAS mutations are **less frequent than PTPN11 mutations**. *PTEN* - **PTEN** is a tumor suppressor gene regulating the PI3K-AKT pathway, involved in various cancers including Cowden syndrome and endometrial cancer. - PTEN mutations are **not associated with JMML** pathogenesis. *APC* - The **APC gene** is a tumor suppressor in the Wnt signaling pathway, critical for colon epithelial regulation. - APC mutations cause **familial adenomatous polyposis (FAP)** and colorectal cancer, but are **not implicated in JMML**.

Q: Which of the following statements is false regarding beta thalassemia major?

Bone marrow iron is depleted. ***Bone marrow iron is depleted*** - In beta thalassemia major, patients typically experience **iron overload** due to repeated blood transfusions, leading to **depleted iron stores** in the bone marrow. - This finding contrasts with conditions where iron stores are preserved or increased, highlighting the pathology of thalassemia. *Growth and development is impaired* - While children with beta thalassemia major may experience growth delay, this statement is **not universally true** for all patients. - Factors such as treatment and iron overload management can influence growth and development outcomes. *Red cell count <4 x 10'2/L* - Normal red cell counts can occur in some patients, particularly in **transfusion-dependent cases**. - Thus, it is not a definitive characteristic of beta thalassemia major, as levels can vary. *Levels of HbA2 < 3.5%* - In beta thalassemia major, HbA2 levels are often **increased**, usually exceeding 3.5% [1]. - This distinguishes it from beta thalassemia trait, where HbA2 is elevated but not to the same extent as in major [1].

Question 1

A patient with anemia has a reticulocyte count of 6% and a hematocrit of 30%. What is the clinical significance of the corrected reticulocyte count?

Accepted Answer

4%, indicating an appropriate response to anemia.

Answer

2%, indicating an inadequate response to anemia.

Answer

6%, suggesting ineffective erythropoiesis.

Answer

3%, consistent with iron deficiency anemia.

Question 2

Which immunohistochemical markers assist in the diagnosis of follicular lymphoma?

Accepted Answer

CD10 and BCL2

Answer

CD20 and CD23

Answer

CD30 and CD15

Answer

CD3 and CD7

Question 3

In a patient with hemolytic anemia, which of the following laboratory findings is most likely to be elevated?

Accepted Answer

Reticulocyte count

Answer

Haptoglobin

Answer

Indirect Bilirubin

Answer

Serum Ferritin

Question 4

A 5-year-old child presents with fatigue, petechiae, and hepatosplenomegaly. Laboratory results show low hemoglobin, low platelets, and high white blood cell count. The peripheral smear reveals blasts with Auer rods. What is the diagnosis?

Accepted Answer

Acute myeloid leukemia

Answer

Acute lymphoblastic leukemia

Answer

Chronic lymphocytic leukemia

Answer

Chronic myeloid leukemia

Question 5

Which formula is essential for calculating the corrected reticulocyte count in an anemic patient?

Accepted Answer

(Reticulocyte count × Hematocrit) / 45

Answer

(Reticulocyte count × Hematocrit) / 50

Answer

(Reticulocyte count × Hematocrit) / 40

Answer

(Reticulocyte count × Hematocrit) / 30

Question 6

Which disease is characterized by the absence of the CD59 protein?

Accepted Answer

Paroxysmal Nocturnal Hemoglobinuria (PNH)

Answer

Atypical Hemolytic Uremic Syndrome (aHUS)

Answer

Hereditary Spherocytosis

Answer

Autoimmune Hemolytic Anemia

Question 7

Which gene is commonly overexpressed in follicular lymphoma?

Accepted Answer

Bcl-2

Answer

Bcl-1

Answer

Bcl-6

Answer

None of the options

Question 8

Which of the following statements about sideroblastic anemia is correct?

Accepted Answer

Prussian blue staining reveals ringed sideroblasts

Answer

All of the options are false

Answer

Severity of the disease is influenced by ALA synthase activity

Answer

Pyridoxine supplementation is the definitive treatment for all types of sideroblastic anemia

Question 9

Which of the following genes is most commonly mutated in Juvenile myelomonocytic leukemia (JMML)?

Accepted Answer

PTPN11

Answer

KRAS

Answer

PTEN

Answer

APC

Question 10

Which of the following statements is false regarding beta thalassemia major?

Accepted Answer

Bone marrow iron is depleted

Answer

Growth and development is impaired

Answer

Red cell count is typically low

Answer

Levels of HbA2 are typically increased

Hematopathology — MCQs

Hematopathology — MCQs

On this page

Practice by Chapter

Want unlimited practice?